Related Experiment Videos
Recent advances in xenotransplantation.
1Molecular Immunogenetics Laboratory, Austin Research Institute, Austin and Repatriation Medical Centre, Studley Road, Heidelberg, Victoria, 3084, Australia. m.sandrin@ari.unimelb.edu.au
Current Opinion in Immunology
|October 6, 1999
Summary
Pig-to-human xenotransplantation faces hyperacute rejection due to anti-Galalpha(1,3)Gal antibodies. New strategies focus on reducing Galalpha(1,3)Gal expression or complement activation to improve transplant success.
Area of Science:
- Xenotransplantation research
- Immunology
- Transgenic technology
Background:
- The primary obstacle in pig-to-human xenotransplantation is hyperacute rejection.
- This rejection is mediated by host anti-Galalpha(1,3)Gal antibodies and complement activation.
- Galalpha(1,3)Gal also plays a role in other forms of xenograft rejection involving immune cells.
Purpose of the Study:
- To review strategies for overcoming hyperacute rejection in xenotransplantation.
- To highlight the role of Galalpha(1,3)Gal in various rejection pathways.
- To discuss the progress of transgenic approaches in clinical trials.
Main Methods:
- Review of existing literature on xenotransplantation rejection mechanisms.
- Analysis of transgenic strategies to modify Galalpha(1,3)Gal expression.
- Examination of complement inhibition techniques.
Main Results:
- Transgenic approaches to eliminate or reduce Galalpha(1,3)Gal are being tested in primate trials.
- These strategies aim to prevent antibody- and complement-dependent hyperacute rejection.
- Emerging evidence points to Galalpha(1,3)Gal's involvement in natural killer cell and monocyte-mediated rejection.
Conclusions:
- Overcoming Galalpha(1,3)Gal-mediated rejection is critical for successful xenotransplantation.
- Transgenic modifications and complement reduction are promising strategies.
- Further research is needed to address Galalpha(1,3)Gal's role in antibody-independent rejection pathways.